Home LiteratureArticle Details
PMID: 18062798 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells.

Clinical and experimental immunology ·Vol. 151 ·No. 2 ·2008-02-00 ·Pages 235-43

Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H, Finnish Multiple Sclerosis and Pregnancy Study Group

Abstract

Multiple sclerosis (MS) ameliorates typically during pregnancy but after the delivery the relapse rate often increases. Our study was conducted to understand the immunoregulatory mechanisms accompanying this phenomenon. MS patients were followed-up prospectively during pregnancy and 6 months postpartum, with immunological characterization of the peripheral blood. Groups of age- and parity-matched healthy pregnant women, and age- and sex-matched non-pregnant women and non-pregnant MS patients were studied as controls. In our patient cohort, the annualized relapse rate was 1.0 +/- 1.0 relapses/woman/year (mean +/- standard deviation) during the year before pregnancy, but dropped to 0.2 +/- 0.9 during the third trimester (P = 0.02). After the delivery the relapse rate increased again to 1.4 +/- 1.9 (1-3 months postpartum versus third trimester P = 0.003). While percentages of peripheral blood CD3, CD4, CD8 and CD19 immune cell subsets were unchanged over the observation period, reduced disease activity during the last trimester was associated with a significant increase in the percentage of circulating CD56(bright) natural killer (NK) cells. Simultaneously, the proportion of circulating CD56(dim) NK cells was clearly reduced. No alteration was noted in CD4+ CD25(high) forkhead box P3+ regulatory T cells. Production of interferon-gamma by peripheral blood lymphocytes was down-regulated significantly during pregnancy in comparison to the postpartum period, resulting in an increased T helper type 2 (Th2) : Th1 ratio during pregnancy. In conclusion, pregnant state in MS patients is characterized by an increase in the percentage of CD56(bright) NK cells and by enhanced Th2 type cytokine secretion. Our findings suggest a potential role for CD56(bright) regulatory NK cells in the control of autoimmune inflammation during pregnancy in MS.

MeSH Terms
Adult CD56 Antigen/blood Down-Regulation/immunology Female Follow-Up Studies Humans Immunophenotyping Interferon-gamma/biosynthesis Interleukin-4/biosynthesis Killer Cells, Natural/immunology Middle Aged Multiple Sclerosis, Relapsing-Remitting/immunology Postpartum Period/immunology Pregnancy Pregnancy Complications/immunology Prospective Studies Receptors, IgG/blood T-Lymphocytes, Regulatory/immunology Th1 Cells/immunology Th2 Cells/immunology
Chemicals
CD56 Antigen Receptors, IgG Interleukin-4 Interferon-gamma
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Airas L
MediCity Research Laboratory, University of Turku, Turku, Finland. laura.airas@utu.fi
Saraste M
Rinta S
Elovaara I
Huang Y-H
Wiendl H
Finnish Multiple Sclerosis and Pregnancy Study Group
References (43)
43 references, click to expand
  1. Tolerance signaling molecules.
    Chem Immunol Allergy. 2005;89:36-48 PMID: 16129951
  2. Consequences of autoimmune thyroiditis before, during and after pregnancy.
    Minerva Endocrinol. 2003 Sep;28(3):247-54 PMID: 14605606
  3. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
    Neurology. 1983 Nov;33(11):1444-52 PMID: 6685237
  4. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2005 Jun;163(1-2):24-30 PMID: 15885305
  5. Pregnancy and rheumatoid arthritis: an overview.
    Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):222-5 PMID: 1285884
  6. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.
    J Exp Med. 2004 Apr 5;199(7):971-9 PMID: 15067033
  7. Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients.
    J Neuroimmunol. 2000 Jun 1;105(1):91-5 PMID: 10713368
  8. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis.
    Neurology. 1999 Apr 12;52(6):1230-8 PMID: 10214749
  9. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127.
    Nat Immunol. 2006 Nov;7(11):1217-24 PMID: 17013389
  10. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system.
    FASEB J. 2006 May;20(7):896-905 PMID: 16675847
  11. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients.
    FASEB J. 2005 Nov;19(13):1902-4 PMID: 16144955
  12. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy.
    Clin Exp Immunol. 1996 Oct;106(1):127-33 PMID: 8870710
  13. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells.
    J Exp Med. 1997 Nov 17;186(10):1677-87 PMID: 9362528
  14. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset.
    Immunology. 2004 May;112(1):38-43 PMID: 15096182
  15. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis.
    Eur J Immunol. 1998 May;28(5):1681-8 PMID: 9603475
  16. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
    Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8 PMID: 15161974
  17. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients.
    Clin Exp Immunol. 2007 Mar;147(3):412-8 PMID: 17302889
  18. The regulatory role of natural killer cells in multiple sclerosis.
    Brain. 2004 Sep;127(Pt 9):1917-27 PMID: 15229129
  19. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity.
    J Neuroimmunol. 2003 Dec;145(1-2):103-14 PMID: 14644036
  20. Treatment of multiple sclerosis with the pregnancy hormone estriol.
    Ann Neurol. 2002 Oct;52(4):421-8 PMID: 12325070
  21. Lymphocyte-vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium.
    J Immunol. 1993 Oct 15;151(8):4228-38 PMID: 8409398
  22. The biology of human natural killer-cell subsets.
    Trends Immunol. 2001 Nov;22(11):633-40 PMID: 11698225
  23. Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity.
    Immunol Lett. 2005 Jan 31;96(2):195-201 PMID: 15585323
  24. How immune mechanisms are affected by pregnancy.
    Vaccine. 2003 Jul 28;21(24):3352-7 PMID: 12850338
  25. Latest advances in understanding preeclampsia.
    Science. 2005 Jun 10;308(5728):1592-4 PMID: 15947178
  26. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis.
    Nat Genet. 2007 Sep;39(9):1108-13 PMID: 17660816
  27. Variations in cytokine mRNA expression during normal human pregnancy.
    Clin Exp Immunol. 2000 Feb;119(2):317-22 PMID: 10632669
  28. NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest.
    J Immunol. 2005 Apr 15;174(8):4590-7 PMID: 15814681
  29. Noninfectious uveitis and pregnancy.
    Am J Ophthalmol. 2003 Jul;136(1):91-8 PMID: 12834675
  30. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein.
    Exp Neurol. 2006 Mar;198(1):136-44 PMID: 16423348
  31. Reproductive immunology 2003: reassessing the Th1/Th2 paradigm?
    Immunol Lett. 2004 Apr 15;92(3):207-14 PMID: 15081613
  32. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.
    Neurol Sci. 2007 Jun;28(3):121-6 PMID: 17603762
  33. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Neurology. 2007 Aug 21;69(8):785-9 PMID: 17709711
  34. T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis.
    Am J Pathol. 2004 Dec;165(6):2069-77 PMID: 15579449
  35. Risk alleles for multiple sclerosis identified by a genomewide study.
    N Engl J Med. 2007 Aug 30;357(9):851-62 PMID: 17660530
  36. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
    Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6 PMID: 16585503
  37. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
    N Engl J Med. 1998 Jul 30;339(5):285-91 PMID: 9682040
  38. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes.
    Biochem Biophys Res Commun. 1998 Apr 28;245(3):933-8 PMID: 9588218
  39. The natural killer cell -- friend or foe in autoimmune disease?
    Scand J Immunol. 2002 May;55(5):432-41 PMID: 11975754
  40. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients.
    J Neurol Sci. 2004 Sep 15;224(1-2):69-76 PMID: 15450773
  41. Evidence that pregnancy specific glycoproteins regulate T-Cell function and inflammatory autoimmune disease during pregnancy.
    Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):231-7 PMID: 15853745
  42. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia.
    Clin Exp Immunol. 1999 Sep;117(3):550-5 PMID: 10469061
  43. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
    Immunol Today. 1993 Jul;14(7):353-6 PMID: 8363725
Article Info
Journal
Clinical and experimental immunology
Abbr.
Clin Exp Immunol
ISSN
1365-2249
Published
2008-02-00
Epub
2007-00-06
Pages
235-43
Language
English
Region
England
NLM ID
0057202
PMCID
PMC2276950
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com